SCHEMBL1624864

SCHEMBL1624864

N#Cc1cccc(COC(=O)C(O)c2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.53
FFAR4 Q5NUL3 1/20 0.53
MAOB P27338 1/20 0.47
GRM4 Q14833 1/20 0.46
TACR1 P25103 1/20 0.46
MRGPRX1 Q96LB2 1/20 0.46
LMNA P02545 1/20 0.45
MRGPRX4 Q96LA9 3/20 0.44
FOLH1 Q04609 1/20 0.44
ALKBH1 Q13686 1/20 0.44
ADAMTS4 O75173 1/20 0.43
MMP13 P45452 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
GPR34 Q9UPC5 1/20 0.43
CNR1 P21554 1/20 0.43
SGMS2 Q8NHU3 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29248543 0.85 FFAR1 (0.50) FFAR1FFAR4MAOBTACR1MRGPRX1
SCHEMBL7566253 0.83 FFAR1 (0.46) FFAR1FFAR4MAOBGRM4TACR1
SCHEMBL11839495 0.81 MAOB (0.51) FFAR1MAOBADAMTS4MMP13
SCHEMBL536227 0.81 ALDH1A1 (0.55) LMNASLC6A2
SCHEMBL5117818 0.81 ALDH1A1 (0.55) LMNASLC6A2
SCHEMBL2231648 0.81 ALDH1A1 (0.55) LMNASLC6A2
SCHEMBL14162421 0.80 GLA (0.52) FFAR1FFAR4MAOBLMNAMRGPRX4
SCHEMBL5549275 0.77 FOLH1 (0.46) FFAR1FFAR4MAOBTACR1LMNA
SCHEMBL14783862 0.77 FFAR1 (0.53) FFAR1FFAR4MAOBLMNAMRGPRX4
SCHEMBL16439821 0.77 FFAR1 (0.53) FFAR1FFAR4MAOBLMNAMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928137-B2 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2011-04-19 US disclosed
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors LIEBESCHUETZ JOHN W 2007-07-05 US disclosed
US-7220781-B2 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2007-05-22 US disclosed
EP-1009758-B1 META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2005-06-01 EP disclosed
US-6740682-B2 TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. TULARIK LIMITED (GB) 2004-05-25 US disclosed
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2002-05-09 US disclosed
EP-1009758-A1 META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS Protherics Molecular Design Limited (GB) 2000-06-21 EP disclosed
WO-1999011658-A1 META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS PROTEUS MOLECULAR DESIGN LTD. (GB) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors SERPINE1, PEPD, PRSS1 FFAR1 3640/4885FFAR4 4362/4885MAOB 1076/4885
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors PEPD, SERPINE1, HPN FFAR1 3972/4885FFAR4 4121/4885MAOB 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.